Vanta Biosciences arm signs Rs 29 crore deal with Emcure Pharma

The official spokesperson of Emcure Pharmaceuticals Ltd. added, ”Service-efficiency, confidentiality and belief in the team in-charge of execution are important factors for selecting the service providers for carrying out our bio-analytical and bio-equivalence studies and we believe that Vayam has the capabilities.”

New Delhi: Vanta Bioscience Limited has recently announced that its step-down subsidiary ‘Vayam Research Solutions Limited’ has entered into a non-exclusive CRO Service Agreement with Emcure Pharmaceuticals Limited, Pune, for providing services of Bio-Analytical and Bio-Equivalence services to the Company for a period of three years from 2019 to 2022.

The CRO Service Agreement provides for a minimum revenue assurance between Rs. 7.00 crores Rs.9.00 crores for the financial year 2019-2020 and Rs. 20.00 crores for the financial year 2020-2021.

Also Read: NPPA fixes retail price of Emcure pharma’s HIV drug

Speaking on the development, Mr Dopesh Raja Mulakala, Managing Director, Vanta Bioscience Limited, said, "This deal broadens our horizon. With a steady and assured revenue, we are further encouraged to shorten the timeframe for dominating the category. We now have state—of—the—art facility and world-class expertise to offer services as per global standards.

"We are confident that we will deliver impeccable results and add continuous value to their business. It is a matter of pride to be associated with an established company like Emcure Pharmaceuticals,” Mulakala added.

The official spokesperson of Emcure Pharmaceuticals Ltd. added, ”Service-efficiency, confidentiality and belief in the team in-charge of execution are important factors for selecting the service providers for carrying out our bio-analytical and bio-equivalence studies and we believe that Vayam has the capabilities.”

Also Read: Emcure launches generic Eribulin at 40 percent lower price in India